Silphium Asset Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Silphium Asset Management’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-8,300	Closed	-$980K	–	54
2020 Q4	$980K	Buy	+8,300	New	+$964K	0.99%	21
2018 Q3	–	Sell	-19,198	Closed	-$1.91M	–	174
2018 Q2	$1.91M	Buy	+19,198	New	+$1.66M	0.6%	36

Other funds holding CBPO

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCP

Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Silphium Asset Management's CBPO Position: Q1 2021 in Review

Silphium Asset Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q1 2021, closing a stake of 8,300 shares — an estimated $980K sold.

Silphium Asset Management first reported a position in CBPO in Q2 2018 and held it in 2 quarters. The position peaked at $1.91M in Q2 2018. 86 funds tracked by Wall St. Rank hold CBPO as of Q1 2021.

Silphium Asset Management reported no remaining China Biologic Products Holdings, Inc. position as of Q1 2021 after selling out during the quarter.
Silphium Asset Management sold 8,300 China Biologic Products Holdings, Inc. shares in Q1 2021, an estimated $980K.
Silphium Asset Management first reported a position in China Biologic Products Holdings, Inc. in Q2 2018 and held it in 2 quarters.
Silphium Asset Management's China Biologic Products Holdings, Inc. position peaked at $1.91M in Q2 2018.
86 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2021.

Based on Silphium Asset Management's 13F filing for Q1 2021, filed 30 Jan 2025.